Overcoming Immunotherapy Resistance in Cancer
We are developing therapeutics that target long non-coding RNAs used by tumors to hide from immune system
We are developing therapeutics that target long non-coding RNAs used by tumors to hide from immune system
of cancer patients fail to benefit from immunotherapy. Most patients do not respond or eventually develop resistance to treatment.
global cancer immunotherapy market. Immunotherapy is transforming cancer care and continues to grow rapidly worldwide.
of patients could benefit from improved immunotherapy response.
Immunotherapy has transformed cancer treatment, yet over 70% of treated patients fail to respond or eventually develop resistance. Tumor-intrinsic mechanisms of immune suppression remain a major barrier to durable anti-tumor responses.
At Oncolinc, we are targeting long non-coding RNAs, which represent an untapped class of therapeutic targets capable of reshaping the tumor immune microenvironment.
A major unmet need exists for therapies that restore immune visibility in tumours currently invisible to the patient's immune cells.
We are developing antisense oligonucleotide therapeutics that selectively target immunosuppressive long non-coding RNAs (lncRNAs) that cause tumor progression and immune evasion.
By silencing these lncRNAs, we aim to:
Advancing new strategies to overcome tumor immune suppression offers the potential to improve survival outcomes and quality of life for patients facing cancers that remain resistant to current treatments.
Novel Mechanism of Action
Targets tumor-intrinsic mechanisms of immune evasion with the goal of restoring immune recognition and anti-tumor responses.
Precision Targeting
Long non-coding RNAs (lncRNAs) are often highly tumor-enriched, creating opportunities for selective therapeutic targeting.
First-in-Class Therapeutic Strategy
Advancing a novel lncRNA-targeting approach designed to address immune resistance across multiple solid tumor types.
Biomarker-Informed Development
Patient stratification strategies may enable more precise treatment selection and improve therapeutic development.
Monotherapy & Combination Therapy Potential
Potential use alongside existing therapies, including immune checkpoint inhibitors.
Aligned with Oncology Practice
Addresses a major unmet need within a rapidly growing immuno-oncology landscape and existing treatment infrastructure.
Have questions about our cancer therapies or partnership opportunities? Reach out to Oncolinc Therapeutics and join us in advancing cancer care.
Oncolinc Therapeutics Inc.
Copyright © 2026 Oncolinc Therapeutics Inc. All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.